Cerus Co. (NASDAQ:CERS) insider Chrystal Menard sold 26,535 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.59, for a total value of $95,260.65. Following the transaction, the insider now owns 7,500 shares in the company, valued at $26,925. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ CERS traded up $0.43 during trading on Thursday, reaching $4.47. 837,382 shares of the company traded hands, compared to its average volume of 2,274,683. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.16 and a current ratio of 2.55. The stock’s 50 day moving average price is $4.66 and its two-hundred day moving average price is $4.51. The company has a market cap of $624.34 million, a price-to-earnings ratio of -8.60 and a beta of 1.19. Cerus Co. has a 1-year low of $2.71 and a 1-year high of $6.64.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $20.92 million for the quarter, compared to analyst estimates of $20.90 million. Cerus had a negative net margin of 95.44% and a negative return on equity of 112.64%. Equities research analysts expect that Cerus Co. will post -0.44 EPS for the current fiscal year.

Several brokerages recently issued reports on CERS. ValuEngine upgraded Cerus from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. BTIG Research assumed coverage on Cerus in a report on Wednesday, February 26th. They set a “buy” rating and a $7.00 price objective on the stock. BidaskClub downgraded Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Zacks Investment Research raised Cerus from a “sell” rating to a “hold” rating in a report on Wednesday, March 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $7.33.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CVA Family Office LLC acquired a new position in shares of Cerus in the 4th quarter worth approximately $42,000. Great West Life Assurance Co. Can acquired a new position in shares of Cerus in the 4th quarter worth approximately $44,000. Exchange Traded Concepts LLC acquired a new position in shares of Cerus in the 4th quarter worth approximately $57,000. Virtu Financial LLC acquired a new position in shares of Cerus in the 4th quarter worth approximately $77,000. Finally, Alpine Global Management LLC acquired a new position in shares of Cerus in the 4th quarter worth approximately $78,000. 69.56% of the stock is currently owned by institutional investors.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: How is diluted EPS different from basic EPS?

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.